| answer text |
<p>Most new drugs and significant licence indications are assessed by the National
Institute for Health and Care Excellence (NICE) through its technology appraisal programme,
through which NICE has been able to recommend a significant number of drugs for the
treatment of rare cancers and other diseases for routine use on the National Health
Service. NICE also operates a separate Highly Specialised Technology evaluation programme
for the evaluation of a very small number of treatments for very rare diseases.</p><p>The
methods and processes NICE uses in the development of its guidance are internationally
respected, have been developed through extensive engagement with a full range of stakeholders,
including the Department, and are regularly reviewed to ensure that they remain fit
for purpose.</p>
|
 |
